Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
Big majority in Germany call Berlin's efforts on gas prices too weak- Bruno Mars tour 2026: How to get tickets for 'The Romantic Tour,' presale times, prices and more
- Pick Your Favored kind of soup
- Jesse Jackson hospitalized, under observation for a neurodegenerative condition
- Gauging the Upsides and downsides of Visas: A Complete Aide
- Architect Frank Gehry has died: See his most iconic buildings
- Find the Marvels of the World with These Travels
- The cave was pitch black – so to create this magical underwater shot, the photographer had to use all his camera expertise...
- Jillian Michaels put me at the center of a body positivity debate. She's not entirely wrong about obesity.
